Gordon Williams, MD
Internal Medicine · Eden, NCNPI 1194768382
Payments from drug & device makers
Across 143 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$442
- Pfizer$234
- Boehringer Ingelheim$182
- Amgen$163
- AstraZeneca$115
- Novo Nordisk$112
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,386100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $442 |
| Pfizer | 15 | $234 |
| Boehringer Ingelheim | 11 | $182 |
| Amgen | 11 | $163 |
| AstraZeneca | 8 | $115 |
| Novo Nordisk | 7 | $112 |
| Exact Sciences | 7 | $106 |
| Merck | 7 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| GSK | 6 | $84 |
| AbbVie | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Sanofi Pasteur Inc. | 3 | $46 |
| Tactile Systems Technology Inc | 1 | $43 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Abbott | 1 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Mylan Specialty L.p. | 1 | $25 |
| Gilead | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Novartis | 1 | $20 |
| Medtronic | 1 | $19 |
| Axonics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Bayer | 1 | $12 |
How this compares
$2,386 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $115,042 |
| JardianceEmpagliflozin | 83 | $92,206 |
| EliquisApixaban | 77 | $78,642 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $66,974 |
| MyrbetriqMirabegron | 61 | $47,130 |
| Repatha SureclickEvolocumab | 64 | $43,257 |
| XareltoRivaroxaban | 40 | $31,702 |
| FarxigaDapagliflozin Propanediol | 28 | $23,041 |
| Spiriva HandihalerTiotropium Bromide | 15 | $11,155 |
| LinzessLinaclotide | 16 | $11,065 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,742 |
| Spiriva RespimatTiotropium Bromide | 16 | $9,337 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $6,822 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,607 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $112 | $115,042104 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $182 | $108,150111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $84 | $83,134104 claims |
| PfizerEliquis | $234 | $78,64277 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $47,13061 claims |
| Johnson & JohnsonXarelto | $14 | $31,70240 claims |
| AstraZenecaFarxiga, Lokelma | $115 | $27,66739 claims |
| AbbVieLinzess | $77 | $11,06516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Eden
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.